<DOC>
	<DOCNO>NCT01357863</DOCNO>
	<brief_summary>The study conduct multicenter prospective observational cohort study , try cover almost Brazilian States , population ErbB2 positive metastatic breast cancer patient , whose disease progress trastuzumab-containing regimen , compare outcome two group : Group 1 : patient receive Lapatinib-capecitabine immediately 1st Trastuzumab progression ( second line treatment ) , Group 2 : patient receive Lapatinib-capecitabine 2 line treatment 1st trastuzumab progression ( third line great ) .</brief_summary>
	<brief_title>Role Early Versus Late Switch Lapatinib-Capecitabine</brief_title>
	<detailed_description>All case ErbB2 positive metastatic breast cancer , receive approved standard treatment lapatinib-capecitabine , trastuzumab-containing regimen progression community set participate observational study , period 12 month observation since start lapatinib-capecitabine treatment .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Women ErbB2+ MBC ( ErbB2 expression confirm immunohistochemistry FISH/CISH , either primary tumor metastasis , accord institution 's common practice ) ; Older 18 year old ; Have receive prior treatment trastuzumabcontaining regimen ErbB2+ breast cancer ; Progressing trastuzumabcontaining regimen either used treatment metastatic disease progress adjuvant /neoadjuvant trastuzumab treatment ; Eligible start standard treatment Lapatinibcapecitabine conventional dos , community setting ; Signed consent participate release information study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Lapatinib</keyword>
	<keyword>Observational Study</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Brazil</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>